A rapid approach to capture the potential bioactive compounds from Rhizoma Drynariae, utilizing disease-associated mutation in calcium sensing receptor to alter the binding affinity for agonists.

doi:10.1016/j.jpba.2023.115253

Article

A rapid approach to capture the potential bioactive compounds from Rhizoma Drynariae, utilizing disease-associated mutation in calcium sensing receptor to alter the binding affinity for agonists.

Journal of pharmaceutical and biomedical analysis - 20 Mar 2023

Meng Kai-Li, Jiao Mei-Zhi, Shi Xian-Gang, Xu Ru, Cheng Pei-Xuan, Lv Hui-Ting, Zheng Xiao-Hui, Xiao Chao-Ni

Abstract excerpt

Rhizoma Drynariae (RD) was used clinically to treat osteoporosis in China due to stimulating bone formation and inhibiting bone resorption, however, the bioactive constituents with the dual effect on bone are still unknown exactly. Disease-causing mutations in calcium sensing receptor (CaSR) can alter parathyroid hormone secretion and affect Ca2+ release from bone and Ca2+ reabsorption from kidney, which gives an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

A rapid approach to capture the potential bioactive compounds from Rhizoma Drynariae, utilizing disease-associated mutation in calcium sensing receptor to alter the binding affinity for agonists.

Abstract excerpt

Topics

Related research